Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer Causes

Lung Cancer Symptoms

Lung Cancer Diagnosis

Epidemiology of Lung Cancer

Lung Cancer Treatments

Lung Cancer Research

Lung Cancer Questions

Lung Cancer Prevention

Lung Cancer Genetics

Lung Cancer Pathogenesis

What Causes Lung Cancer in Non-Smokers?

See more featured articles »

Lung Cancer Prognosis

Lung Cancer: Radiotherapy and Chemotherapy

Types of Lung Cancer Surgery

Lymph Nodes in Lung Cancer

Pulmonary Resection in Lung Cancer

Palliative and End-of-Life Care in Lung Cancer

Secondary Lung Cancer

Carcinogens in Cigarette Smoke

Lung Cancer Screening Procedure

Lung Cancer and Electrolyte Imbalances

Lung Cancer Risk Factors

Everything You Need to Know About Giving Up Cigarettes

Immunotherapy: The Future of Lung Cancer Treatment?

Lung Plethysmography Procedure

Pulmonary Transplant (Lung Transplant)

Latest Lung Cancer News and Research

KinaRx receives SBIR grant to speed up clinical trials for AML and other diseases

Acute myeloid leukemia (AML), an aggressive blood cancer, is one of the most lethal cancers. More than 19,000 new cases are diagnosed a year, and more than 11,000 people a year die from it, according to the American Cancer Society.

3 Jun 2020

Bacteria lurking in cancer cells may affect treatment

Cancer cells are comfy havens for bacteria. That conclusion arises from a rigorous study of over 1,000 tumor samples of different human cancers.

2 Jun 2020

New advance addresses a big challenge with using CRISPR in cancer patients

A mutation unique to certain cancer tumors is a potential homing beacon for safely deploying CRISPR gene editing enzymes to disarm DNA that makes cancer cells resistant to treatment, while ignoring the gene in normal cells where it's critical to healthy function, according to a new study from ChristianaCare's Gene Editing Institute in the journal Molecular Cancer Research.

2 Jun 2020

A moving target identified in small cell lung tumors

Lung cancers account for approximately 25 percent of all cancer deaths. Even among those who do not smoke, 1 in 15 men and 1 in 17 women are expected to develop lung cancer in their lifetime, according to the American Cancer Society.

1 Jun 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

New review analyzes appropriateness of off-pathway cancer care

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan.

30 May 2020

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

30 May 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

Dana-Farber nurse-scientists receive more than $1.3 million for two research projects

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

26 May 2020

New AI tool could predict risk of lung cancer recurrence

Computer scientists working with pathologists have trained an artificial intelligence tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment, as part of Cancer Research UK’s landmark TRACERx study.

26 May 2020

Research looks at COVID-19 in cancer patients

As the world grapples with the COVID-19 pandemic, new questions arise as to the risk posed by the virus to different patient populations, including the elderly and those with underlying disease. A new study published on the preprint server medRxiv* in May 2020 deals with the risk of COVID-19 in the subgroup of patients with cancer.

21 May 2020

Molecular testing rates in most countries less than 50%, IASLC survey finds

Access to targeted therapies for lung cancer depends on accurate identification of patients' biomarkers through molecular testing, but survey results published today in the Journal of Thoracic Oncology suggest that many international clinicians are unaware of evidence-based guidelines that support the use of molecular testing.

20 May 2020

Radiation oncology clinics report fewer patients despite improved safety measures

Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO).

20 May 2020

Cancer biologists identify important drivers of tumor resistance

Cancer biologists at the Mays Cancer Center, home to UT Health San Antonio MD Anderson, have identified important drivers that enable tumors to change their behavior and evade anticancer therapies.

18 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Experts publish a review of lung cancer treatments for patients with COVID-19

Lung cancer patients are at heightened risk for COVID-19 and the reported high mortality rate among lung cancer patients with COVID-19 has given pause to oncologists who are faced with patients with not one, but two severe, life-threatening diseases.

15 May 2020